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INTRODUCTION 
The concept of clinical antibacterial spectrum of 
activity has been developed in order to make the 
summary of product characteristics (SPC) as helpful as 
possible to the clinician faced with prescribing an 
antibiotic empirically. The SPC is an official document 
established at the time of approval for marketing 
(AMM) and delivered by the French Ministry of 
Health: it must necessarily be shown on a l I  documents 
related to ths antibiotic. It includes especially the 
clinical inhcations based on the clinical antibacterial 
spectrum, the pharmacokinetics of the product, and the 
possible side effects. 
Every antibiotic is characterized by a natural 
spectrum of antimicrobial activity that has been 
precisely determined during the initial phases of its 
study, long before it is introduced into clinical practice. 
This spectrum of activity, which includes the strains 
that can be ihb i ted  by the antibiotic, does not vary 
qualitatively, although the percentages of susceptible 
bacterial strains in a species may change over time with 
the development of resistance. For example, peniclllin 
G and vancomycin both include Staphylococcus aureus in 
their spectrum of activity. However, whereas the 
number of strains susceptible to penicillin G is currently 
less than lo%, it is still 100% for vancomycin. 
In the absence or before results of susceptibility 
tests are available, the clinician must select an antibiotic 
which not only includes in its spectrum of activity the 
species most likely responsible for the infection but 
also statistically presents a reasonable chance of being 
active against the particular strain. It is obvious that 
this requirement is more stringent in more severe 
infections. For example, to treat meningitis it is an 
obligation to use the more likely active antibiotics, with 
the lowest risk of resistant strains [l]. 
DETERMINATION OF THE NATURAL SPECTRUM OF 
ACTIVITY OF AN ANTIBIOTIC 
This represents the first step in the study of an anti- 
biotic. Every antibiotic has to be investigated against 
several hundreds of strains belonging to species patho- 
genic for humans. The strains should be representative 
of all of these species, and each species should include 
strains of various origins susceptible or possessing 
definite mechanisms of resistance. The study of a large 
number of strains per species allows the determination 
of the modal minimal inhibitory concentration (MIC) 
of the susceptible population. This value characterizes 
the bacterium-antibiotic pair and allows comparisons 
of activities of different antibiotics. Strains possessing a 
particular mechanism of resistance must also be studied. 
Their modal MICs correlated to the pharmacokinetic 
data delineate some of the questions which should be 
answered by the clinical trials. 
Strains that are not included in the natural 
spectrum of activity of an antibiotic are referred to as 
being naturally resistant to this antibiotic. Some natural 
resistance characteristics are of important taxonomic 
value (e.g. polymyxin and Serrutia). 
CLINICAL CATEGORIZATION 
The clinical categorization is based on the study of the 
MIC distribution against bacterial populations within a 
representative sample of strains, detection of mechan- 
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isms of resistance and comparison with clinical and 
pharmacokinetic data [2-71. These results in the 
determination of two critical concentration break- 
points, high and low (Figure 2), separating the three 
clinical categories enable the clinician to anticipate the 
effect of antibiotic therapy. 
Susceptible strain: the probability of therapeutic 
response is very high. 
0 Resistant strain: the risk of non-response to 
treatment is high. 
0 Intermedate strain: the therapeutic outcome is un- 
predictable. This category is heterogeneous because 
it combines a buffer zone due to biological methods, 
a zone of uncertainty due to variation in clinical 
response, and lastly particular cases where a bacterial 
strain could be targeted when local antibiotic 
concentrations are high (urine). 
CLINICAL SPECTRUM OF A N  ANTIBIOTIC (Table 1) 
The clinical spectrum of an antibiotic is a formulation 
which is based upon the ability of the antibiotic to cure 
infections due to the designated bacteria [S]. Thus, 
bacterial species are included only when clinical 
efficacy was demonstrated and relevant for the approved 
indications. For example, Legionella spp. should be 
included in the clinical spectra of macrolides, 
fluoroquinolones and rifampicin but not in those of 
aminoglycosides or p-lactams, despite their in vitro 
activity. Certain species are not included in the 
spectrum of activity: these are species which cause local 
infections in sites where the antibiotic does not diffuse 
in sufficient concentrations even though it is active 
in vitro (e.g. Neisseria meningitidis and first-generation 
cephalosporins or macrolides) . This also involves 
species which cause infections for which the antibiotic 
has not been approved for certain therapeutic in- 
dications by the marketing authorization submission, 
since the demonstration of therapeutic efficacy in these 
cases has not been provided. 
The clinical spectrum of activity of an antibiotic 
takes the following items into account [4-61: 
0 natural spectrum of activity 
0 modal MICs of susceptible strains 
0 pharmacokinetic data 
clinical results 
Ideally, the clinical spectrum of an antibiotic should 
include the necessary information on the epidemiology 
of resistant strains. This important information is, 
however, difficult to include without some generaliz- 
ation. 
Table 1 Clinical spectrum of activity of erythromycin 
~~~ ~ ~~ ~~ ~ 
Usually susceptible species (MIC S 1 mg/L) 
Streptococcus p y o p i e s  
Modal MIC = 0.03 mg/L 
Frequency of acquired resistance: <lo% in France 
Excellent clinical activity (sore throats) 
Moderately susceptible species (MIC 2-4 mg/L) 
Haemopliilus injrrewzae 
Modal MIC = 4 mg/L for 60% of strains (very low level natural 
No acquired resistance 
Clinical results vary depending on the antibiotic concentrations 
resistance) 
in the body 
Resistant strains (MIC > 4 mg/L) 
Esrheritlzia coli 
Modal MIC = 32-64 mg/L 
Natural resistance is incompatible with therapy 
Methicillin-resistant Staplrylorocrirs aureus 
Frequency of acquired resistance: approximately 95% of strains 
MIC 264 mg/L 
Inconstantly susceptible species 
Streptococcus pneumoniae 
Modal MIC for susceptible strains = 0.03 mg/L 
Frequency of acquired resistance: 30-40% 
Bacterial resistance to antibiotics evolves in a 
highly variable way depending on the time and the 
places (ward in a hospital section in a city, region, etc.). 
In some cases after a period of time, the prevalence 
rates of resistant strains stabilize and even become 
comparable in different geographic areas (e.g. Staphylo- 
coccus and Haemophifus infuenzae producing penicil- 
linase) . 
In other situations, the resistance rate will vary 
considerably from one country to another; for example, 
resistance to macrolides in Streptococcus pneumoniae is 
high in France (30-40%) and still low in the USA 
(<5%) [9]. Undue applications of foreign epidemio- 
logic data in a country may have serious consequences. 
To prescribe an antibiotic with the maximum 
chance of clinical response, the physician should know 
the status of resistance of the major species of bacteria 
in the location where he or she is practicing. This 
requires, up to date epidemiologic data on resistance 
and the analysis of clinical failures with accurate 
bacteriologic documentation. 
To recognize the resistant strains in a population of 
strains, the MIC 50% and the MIC 90% are of limited 
value, since the interval between MIC 50% and MIC 
90% is the only indication of possible resistant 
populations. We think that the histogram of the strains 
tested is more informative than the cumulative 
percentage, since it shows the distribution and the 
number of subpopulations. 
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Figure 1 MIC distributions: (a, b), unimodal distribution; (c), bimodal distribution; (d), multimodal distribution. 
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Figure 2 Classification of species in the antibacterial spectrum of activity of an antibiotic: (a), usually susceptible species; 
(b), resistant species; (c), moderately susceptible species; (d), non-constantly susceptible species. (=low breakpoint or suscepti- 
bility breakpoint; C = h g h  breakpoint or resistance breakpoint. 
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The distribution of MICs can thus differ (Figures 
1 and 2), as follows: 
0 Unimodal distribution: all bacteria of a species belong 
to a given population, i.e., susceptible or resistant. 
0 Bimodal distribution: there are two well indi- 
vidualized populations, one susceptible and the other 
resistant. 
Multimodal distribution: there are several popula- 
tions having various levels of susceptibility. 
To facilitate the classification of species, four classes 
have been proposed, as follows: 
Usually susceptible species 
These are species which are within the antibiotic’s 
natural spectrum of activity and among which the 
percentage of strains with acquired resistance is low, less 
than 10%. The distribution of MICs is generally 
unimodal and below the lowest critical concentration. 
The physician can thus use this antibiotic at usual doses 
to treat an infection with a maximum safety, since the 
clinical trials have established the indication. 
Species that are moderately susceptible or of 
intermediate susceptibility 
These species are less susceptible to the antibiotic. This 
is the case with Haemophifus influenzae with respect to 
macrolides. This situation is characterized by an MIC 
50% superior or equal at the low breakpoint and by an 
MIC 90% inferior or equal at the high breakpoint. To 
treat an infection caused by these bacteria, high doses 
of the antibiotic must be used (whenever possible) or 
the infection must be located in a site where the 
antibiotic concentrations are particularly high, greater 
than the MIC. 
Resistant species 
In this case, the MICs are distributed beyond the high 
critical concentration. The following situations can be 
distinguished: 
Species whch are naturally resistant to the antibiotic 
and are not included in its spectrum of activity (e.g. 
Staphylococcus aureus and colistin) . 
0 Species within the initial spectrum of activity of the 
antibiotic but in which the percentage of acquired 
resistance is high (>SO%) and established with suf- 
ficient data in a country or at an international level 
such that this antibiotic can no longer have, outside 
of exceptional cases, any indication in treatment of 
an infection caused by a strain belonging to one of 
these species. This is the case with penicillin G and 
Staphylococcus aureus. However, when the in vitro test 
shows that the strain is susceptible, its use remains 
possible (for example, methicillin-resistant staphylo- 
cocci are resistant to currently used fluoroquinolones 
in France at a rate of 80-90%; these agents, although 
not recommended in empirical therapy, may have a 
clinical indication in few documented cases). 
The class where the species are listed as 
non-constantly susceptible 
This is based on available epidemiologic information 
on bacterial resistance. Although the information 
depends on the time and location, we think that this 
class adjusts and updates the clinical spectrum. 
It is important to call the attention of the prescriber 
to existing rates of resistant strains higher than lo%, so 
that in treating severe infections caused by a strain 
belonging to one of these species, the antibiotic suscep- 
tibility testing and the awareness of the physician wdl 
facilitate the decision and likely improve the outcome. 
In conclusion, the antibacterial spectrum of activity of 
an antibiotic includes species which are initially 
susceptible: this is an invariable first dimension, the 
‘range’ of the spectrum. 
In addition to this initial parameter, a second 
related to epidemiologic changes in resistance must 
also be considered. The latter data must be updated 
regularly to take into account changes in the incidence 
of resistant strains within some species which have 
previously known mechanism of resistance and the 
development of new mechanisms of resistance. 
Lastly, the clinician’s role is to add a third dimen- 
sion, which is crucial: this is the notion of clinical 
success or failure. 
As a result of these notions, the clinical anti- 
bacterial spectrum of activity of an antibiotic provides 
the prescribing physician with updated information 
enabling him or her to choose the most suitable 
antibiotic to treat his or her patient. 
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